Bromo-DragonFLY

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-24srcCharacterization of synthetic routes to 'Bromo-DragonFLY' and benzodifuranyl isopropylamine homologues utilizing ketone intermediates. Part 1: synthesis of ketone precursors
5. 2026-09-24srcCharacterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes.
6. 2026-09-24srcPhenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings
7. 2026-09-24srcMass poisoning with NPS: 2C-E and Bromo-DragonFly
8. 2026-09-24srcIdentification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays
9. 2026-09-24srcA fatal poisoning involving Bromo-Dragonfly
10. 2026-09-24srcIn Vitro Characterization of New Psychoactive Substances at μ-Opioid, CB1, 5HT1A, and 5-HT2A Receptors
11. 2026-09-24srcComparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs
12. 2026-09-24srcBromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A
13. 2026-09-24srcTramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice.
14. 2026-09-24srcToxicity of Bromo-DragonFLY as a New Psychoactive Substance: Application of In Silico Methods for the Prediction of Key Toxicological Parameters Important to Clinical and Forensic Toxicology
15. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
16. 2026-09-24src1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.
17. 2026-09-24srcADME of Bromo-DragonFLY as an example of a new psychoactive substance (NPS) - application of in silico methods for prediction: absorption, distribution, metabolism and excretion
18. 2026-09-24srcReports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
19. 2026-09-24srcPharmacological profile of novel psychoactive benzofurans
20. 2026-09-24srcTranslocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity
21. 2026-09-24srcA novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor
22. 2026-09-24srcWhat is Bromo-DragonFly? (Clinical toxicology summary)
23. 2026-09-24srcBromo-DragonFLY Legal Status by Jurisdiction
24. 2026-09-24srcBromo-Dragonfly Death and Hospitalization in Sweden (September 2007)
25. 2026-09-04issueIssued emergency
26. 2026-09-04issueIssued info_card
27. 2026-09-04issueIssued notice
28. 2026-06-04proposal32 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
29. 2026-06-04publicationPublication — backfill
30. 2026-05-03revisionRevision 1
31. 2026-05-03absenceSearched ClinicalTrials.gov for "Bromo-DragonFLY" — no results
32. 2026-05-03genGeneration — pipeline-v5pipeline-v5
33. 2026-05-03rungeneration run

The same entries, as forms: six forms.